Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Mitnick, Carole D ^a,b,c   Franke, Molly F ^a,b   Rich, Michael L ^b,c   Alcantara Viru, Felix A ^d   Appleton, Sasha C ^b   Atwood, Sidney S ^c   Bayona, Jaime N ^b,d   Bonilla, Cesar A ^e   Chalco, Katiuska ^d   Fraser, Hamish S F ^b,c   Furin, Jennifer J ^f   Guerra, Dalia ^d   Hurtado, Rocio M ^g,h   Joseph, Keith ^b,c   Llaro, Karim ^d   Mestanza, Lorena ^d   Mukherjee, Joia S ^a,b,c   Muñoz, Maribel ^d   Palacios, Eda ^d   Sanchez, Epifanio ⁱ   Seung, Kwonjune J ^b,c   Shin, Sonya S ^b,c   Sloutsky, Alexander ^j   Tolman, Arielle W ^a   Becerra, Mercedes C ^a,b,c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b PARTNERS IN HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d SOCIOS EN SALUD   (Peru)

^e MINISTERIO DE SALUD   (Peru)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h Global Health Committee   (United States)

ⁱ Hospital Nacional Sergio E Bernales   (Peru)

^j Massachusetts Supranational TB Reference Laboratory   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PERU; RETROSPECTIVE STUDY;

ANALYSIS OF VARIANCE; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84874828197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058664     Document Type: Article

References (59)

1. World Health Organization (2012) Global Tuberculosis Report 2012. Geneva: World Health Organizatioon.
2. American Thoracic Society, Centers for Disease Control and Prevention (2000) Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 161: 1376-1395.
3. World Health Organization (2006) Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization.
4. Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J, Becerra MC, et al. (2004) Identifying early treatment failure on Category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 8: 52-58.
5. Quy HT, Lan NT, Borgdorff MW, Grosset J, Linh PD, et al. (2003) Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 7: 631-636.
6. Caminero JA, (2006) Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 10: 829-837.
7. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283: 2537-2545.
8. Toczek A, Cox H, Cros PD, Cooke G, Ford N (2012) Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis [Review article]. Int J Tuberc Lung Dis.
9. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, et al. (2007) Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 5: 857-871.
10. Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, et al. (2010) Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 182: 426-432.
11. Leung EC, Leung CC, Kam KM, Yew WW, Chang KC, et al. (2012) Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city. Eur Respir J.
12. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, et al. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: 924-926.
13. World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: World Health Organization.
14. Cobelens FG, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, et al. (2008) Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med 5: e150.
15. Mitnick C, Horsburgh CR Jr, (2010) Encouraging news for multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 182: 1337-1338.
16. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, et al. (2004) Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363: 474-481.
17. World Health Organization (2006) Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization.
18. World Health Organization (2008) Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update 2008. Geneva: World Health Organization.
19. Partners In Health, World Health Organization (2010) Management of MDR-TB: A field guide. Geneva: World Health Organization.
20. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, et al. (2008) Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 359: 563-574.
21. Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, et al. (2008) Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 46: 1844-1851.
22. Becerra MC, Appleton SC, Franke MF, Chalco K, Bayona J, et al. (2010) Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. Clin Infect Dis 51: 709-711.
23. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, et al. (2013) Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis.
24. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, et al. (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348: 119-128.
25. Partners In Health, Harvard Medical School, Bill & Melinda Gates Foundation (2002) A DOTS-Plus handbook: guide to the community-based treatment of MDR-TB. Boston, MA: Harvard Medical School.
26. Partners In Health (2003) The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis. Boston, MA: Partners In Health.
27. Sweetland A, Acha J, Guerra D (2002) Enhancing adherence: the role of group psychotherapy in the treatment of MDR-TB in urban Peru. In: Cohen A, Kleinman A, Saraceno BE, editors. World Mental Health Casebook: Social and Mental Programs in Low-Income Countries. New York: Plenum Press.
28. Chalco K, Wu DY, Mestanza L, Munoz M, Llaro K, et al. (2006) Nurses as providers of emotional support to patients with MDR-TB. Int Nurs Rev 53: 253-260.
29. Somocurcio JG, Sotomayor A, Shin S, Portilla S, Valcarcel M, et al. (2007) Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 62: 416-421.
30. Fraser HS, Jazayeri D, Mitnick CD, Mukherjee JS, Bayona J (2002) Informatics tools to monitor progress and outcomes of patients with drug resistant tuberculosis in Peru. Proc AMIA Symp: 270-274.
31. Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, et al. (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359: 1980-1989.
32. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, et al. (2005) Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9: 640-645.
33. Kalbfleisch JD, Prentice RL (1980) The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc.
34. Stricker BH, Stijnen T, (2010) Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 25: 245-251.
35. van Walraven C, Davis D, Forster AJ, Wells GA, (2004) Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 57: 672-682.
36. Rich ML, Socci AR, Mitnick CD, Nardell EA, Becerra MC, et al. (2006) Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis 10: 290-296.
37. Ministerio de Salud (2006) Norma tecnica de salud para el control de la tuberculosis. Lima, Peru: Ministerio de Salud.
38. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM, (2009) Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 4: e6914.
39. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN, (1996) Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 153: 317-324.
40. Flament-Saillour M, Robert J, Jarlier V, Grosset J, (1999) Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 160: 587-593.
41. Waisman JL, Palmero DJ, Alberti FA, Guemes Gurtubay JL, Francos JL, et al. (2001) [Improved prognosis in HIV/AIDS related multi-drug resistant tuberculosis patients treated with highly active antiretroviral therapy]. Medicina (B Aires) 61: 810-814.
42. Palacios E, Franke M, Munoz M, Hurtado R, Dallman R, et al. (2012) HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis 16: 348-354.
43. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, et al. (2011) WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38: 516-528.
44. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, et al. (2009) Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9: 153-161.
45. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405.
46. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, et al. (2006) Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 144: 650-659.
47. Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, et al. (2011) Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 133: 529-534.
48. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, et al. (2010) Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182: 684-692.
49. Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, et al. (2009) Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 53: 4498-4500.
50. Matrat S, Veziris N, Mayer C, Jarlier V, Truffot-Pernot C, et al. (2006) Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother 50: 4170-4173.
51. Ginsburg AS, Grosset JH, Bishai WR, (2003) Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 3: 432-442.
52. Devasia RA, Blackman A, May C, Eden S, Smith T, et al. (2009) Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother 63: 1173-1178.
53. Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, et al. (2009) High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 53: 5064-5068.
54. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, et al. (2006) Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194: 479-485.
55. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization.
56. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance (2008) Anti-Tuberculosis Drug Resistance in the World: Fourth Global Report. Geneva: World Health Organization.
57. Shah NS, Richardson J, Moodley P, Moodley S, Babaria P, et al. (2011) Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis 17: 510-513.
58. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C, (2012) Totally drug-resistant tuberculosis in India. Clin Infect Dis 54: 579-581.
59. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, et al. (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136: 420-425.